help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism Vol. 50, No. 1 40-45
doi:10.1210/jcem-50-1-40
Copyright © 1980 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KONO, T.
Right arrow Articles by ENDO, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KONO, T.
Right arrow Articles by ENDO, J.

Biological Activity of des-Asp1-Angiotensin I in Man*

TSUYOSHI KONO, FUMITAKE IKEDA, FUMIMARO OSEKO, HIROO IMURA and JIRO ENDO

Second Division, Department of Internal Medicine, Kyoto University School of Medicine Shogoin, Sakyo-ku, Kyoto 606, Japan
College of Medical Technology, Kyoto University Shogoin, Sakyo-ku, Kyoto 606, Japan

Address requests for reprints to: Tsuyoshi Kono, M.D., Second Division, Department of Internal Medicine, Kyoto University School of Medicine, Shogoin, Sakyo-ku, Kyoyo 606, Japan.

The biological activity of des-Asp1-angiotensin I (des-Asp1-AI) was studied in five normal men. An iv infusion of 300 ng (258 pmol)/kg·min des-Asp1-AI caused a remarkable rise in blood pressure, a decrease in PRA, and an increase in plasma aldosterone concentration. The pressor and steroidogenic actions of this dose of des-Asp1-AI were slightly less than those of 100 ng (111 pmol)/kg-min des-Asp1-angiotensin II [angiotensin III (AIII)] which we reported previously and were abolished by a single oral administration of 100 mg of a converting enzyme inhibitor, SQ 14225. These results indicate that in man, as in animals, a rise in blood pressure and an increase in plasma aldosterone concentration after an infusion of des-Asp1-AI are entirely due to the actions of AIII converted from this nonapeptide, and that the conversion rate of des-Asp1-AI to AIII in normal men is less than 43%. This is much less than the conversion rate of angiotensin I to angiotensin II. It seems unlikely that des-Asp1-AI has physiological significance in the human reninangiotensin-aldosterone system.

* This work was supported by Grant 457598 from the Ministry of Education in Japan.

Received February 12, 1979.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society